Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Beats Estimates By $0.07 EPS

Dogwood Therapeutics (NASDAQ:DWTX) issued its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07, Zacks reports.

Dogwood Therapeutics Trading Up 4.6%

Shares of DWTX stock traded up $0.09 during trading hours on Thursday, hitting $1.95. The company’s stock had a trading volume of 57,773 shares, compared to its average volume of 80,034. The stock has a market cap of $64.96 million, a PE ratio of -0.10 and a beta of 1.68. Dogwood Therapeutics has a 12-month low of $1.28 and a 12-month high of $9.50. The company has a 50 day moving average of $2.14 and a 200 day moving average of $3.68.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Weiss Ratings downgraded Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Dogwood Therapeutics in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical?stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high?throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.